Free Trial

Cannon Global Investment Management LLC Purchases Shares of 47,500 aTyr Pharma, Inc. (NASDAQ:ATYR)

aTyr Pharma logo with Medical background

Cannon Global Investment Management LLC acquired a new position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 47,500 shares of the company's stock, valued at approximately $143,000. Cannon Global Investment Management LLC owned 0.05% of aTyr Pharma as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $144,000. Victory Capital Management Inc. acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $37,000. Raymond James Financial Inc. acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $39,000. Farther Finance Advisors LLC acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $88,000. Finally, American Century Companies Inc. bought a new stake in shares of aTyr Pharma in the fourth quarter worth about $319,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ATYR. Wells Fargo & Company increased their price target on aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, June 20th. HC Wainwright restated a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $20.20.

View Our Latest Stock Report on aTyr Pharma

aTyr Pharma Stock Down 0.5%

ATYR traded down $0.03 during trading on Friday, hitting $5.25. The company had a trading volume of 2,380,688 shares, compared to its average volume of 1,240,670. The company has a market capitalization of $467.61 million, a PE ratio of -6.49 and a beta of 0.89. aTyr Pharma, Inc. has a one year low of $1.48 and a one year high of $5.98. The firm's 50-day moving average price is $4.38 and its 200 day moving average price is $3.80. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities analysts expect that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.

aTyr Pharma Company Profile

(Free Report)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Featured Articles

Institutional Ownership by Quarter for aTyr Pharma (NASDAQ:ATYR)

Should You Invest $1,000 in aTyr Pharma Right Now?

Before you consider aTyr Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.

While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines